Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an expert said.
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.
Surveyed individuals who identified as a racial or ethnic minority reported difficulties discussing cancer diagnosis and treatment. Typical stories shared about “going flat” after a mastectomy may not ...
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data. SHR-A1921, a novel antibody-drug conjugate (ADC) demonstrated activity ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback